<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="54157"><DrugName>rivoglitazone (ophthalmic), Santen</DrugName><DrugNamesKey><Name id="42811188">rivoglitazone</Name></DrugNamesKey><DrugSynonyms><Name><Value>CS-011</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>rivoglitazone</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>rivoglitazone (ophthalmic), Santen</Value></Name><Name><Value>CS-011 (ophthalmic), Santen</Value></Name><Name><Value>DE-101</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>185428-18-6</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="19658">Sankyo Co Ltd</CompanyOriginator><CompaniesSecondary><Company id="19658">Sankyo Co Ltd</Company><Company id="19670">Santen Pharmaceutical Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="54157" type="Drug"><TargetEntity id="281436" type="siDrug">Rivoglitazone hydrochloride</TargetEntity></SourceEntity><SourceEntity id="19658" type="Company"><TargetEntity id="5000284515" type="organizationId">Sankyo Co Ltd Pharmaceutical</TargetEntity></SourceEntity><SourceEntity id="19670" type="Company"><TargetEntity id="4295877908" type="organizationId">Santen Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1146" type="ciIndication"><TargetEntity id="10061446" type="MEDDRA"></TargetEntity><TargetEntity id="D003229" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="3016" type="ciIndication"><TargetEntity id="H04.12" type="ICD10"></TargetEntity><TargetEntity id="10048221" type="MEDDRA"></TargetEntity><TargetEntity id="D014985" type="MeSH"></TargetEntity><TargetEntity id="-455555105" type="omicsDisease"></TargetEntity><TargetEntity id="773" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="79" type="ciIndication"><TargetEntity id="10061453" type="MEDDRA"></TargetEntity><TargetEntity id="D003316" type="MeSH"></TargetEntity><TargetEntity id="-1408327525" type="omicsDisease"></TargetEntity><TargetEntity id="769" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2480" type="Action"><TargetEntity id="895" type="Mechanism">PPARgamma Agonists</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-01596" type="ciTarget"><TargetEntity id="125063490854683" type="siTarget">Peroxisome proliferator-activated receptor gamma</TargetEntity><TargetEntity id="611" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="1146">Conjunctiva disease</Indication><Indication id="3016">Xerophthalmia</Indication><Indication id="79">Corneal disease</Indication></IndicationsSecondary><ActionsPrimary><Action id="2480">PPAR gamma agonist</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="15128">Ophthalmological agent</Action></ActionsSecondary><Technologies><Technology id="620">Ophthalmic formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>S1</Code><Name>OPHTHALMOLOGICALS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-12-08T17:20:02.000Z</LastModificationDate><ChangeDateLast>2016-09-27T00:00:00.000Z</ChangeDateLast><AddedDate>2005-10-03T11:00:22.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="19670" linkType="Company"&gt;Santen&lt;/ulink&gt;, under license from &lt;ulink linkID="19658" linkType="Company"&gt;Sankyo&lt;/ulink&gt;, was developing an ophthalmic formulation of rivoglitazone (CS-011; DE-101), a glitazone (thiazolidinedione) PPAR gamma agonist, for the potential  treatment of corneal and conjunctival epithelial disorders, including dry eye [&lt;ulink linkID="626285" linkType="Reference"&gt;626285&lt;/ulink&gt;], [&lt;ulink linkID="1091916" linkType="Reference"&gt;1091916&lt;/ulink&gt;], [&lt;ulink linkID="1090296" linkType="Reference"&gt;1090296&lt;/ulink&gt;]. By March 2007, the drug was in phase II trials in the US [&lt;ulink linkID="846387" linkType="Reference"&gt;846387&lt;/ulink&gt;]. By March 2009, the drug was listed as being in phase II development in  Japan [&lt;ulink linkID="1091916" linkType="Reference"&gt;1091916&lt;/ulink&gt;], [&lt;ulink linkID="1090296" linkType="Reference"&gt;1090296&lt;/ulink&gt;]. By May 2011, phase IIb in Japan had been completed [&lt;ulink linkID="1211828" linkType="Reference"&gt;1211828&lt;/ulink&gt;]; by November 2011, a US phase II trial had been initiated [&lt;ulink linkID="1235381" linkType="Reference"&gt;1235381&lt;/ulink&gt;]. However, in May 2013, development of the drug was discontinued as the company judged that the expected achievement criteria would not be met [&lt;ulink linkID="1461809" linkType="Reference"&gt;1461809&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Sankyo is developing &lt;ulink linkID="23520" linkType="Drug"&gt;rivoglitazone&lt;/ulink&gt; for the potential treatment of type 2 diabetes. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;By May 2011, phase IIb trials had been completed in Japan, phase I/II trials had been completed in the US and a US phase II trial was being prepared [&lt;ulink linkID="1211828" linkType="Reference"&gt;1211828&lt;/ulink&gt;]. By November 2011, the phase II trial for corneal and conjunctival epithelial disorder had been initiated in the US [&lt;ulink linkID="1235381" linkType="Reference"&gt;1235381&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2010, a multicenter, randomized, double-blind, parallel-group, phase I/II trial (&lt;ulink linkID="66256" linkType="Protocol"&gt;NCT01118754&lt;/ulink&gt;) began in the US to assess the safety and efficacy of rivoglitazone in patients with dry eye (n = 132). The primary endpoints were total fluorescein corneal staining and ocular symptom severity. The study was due to complete in March 2011 [&lt;ulink linkID="1142444" linkType="Reference"&gt;1142444&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2007, the drug was in phase II trials in the US [&lt;ulink linkID="836616" linkType="Reference"&gt;836616&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2006, the drug was in phase I trials in the US [&lt;ulink linkID="755838" linkType="Reference"&gt;755838&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In September 2005, Santen licensed worldwide rights to the drug for corneal and conjunctival epithelial disorders, including dry eye from Sankyo. Sankyo retained the option to copromote the drug in Japan [&lt;ulink linkID="626285" linkType="Reference"&gt;626285&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="PA2980770" linkType="Patent"&gt;WO-2005039574&lt;/ulink&gt;, submitted in May 2005 by Santen, claims use of rivoglitazone for treating and preventing keratoconjunctival disorders.&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="19670">Santen Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1146">Conjunctiva disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-05-08T00:00:00.000Z</StatusDate><Source id="1461809" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19670">Santen Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="1146">Conjunctiva disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-05-08T00:00:00.000Z</StatusDate><Source id="1461809" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19670">Santen Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="3016">Xerophthalmia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-05-08T00:00:00.000Z</StatusDate><Source id="1461809" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19670">Santen Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="79">Corneal disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-05-08T00:00:00.000Z</StatusDate><Source id="1461809" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19670">Santen Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="79">Corneal disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-05-08T00:00:00.000Z</StatusDate><Source id="1461809" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19670">Santen Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="3016">Xerophthalmia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-05-08T00:00:00.000Z</StatusDate><Source id="1461809" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19658">Sankyo Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1146">Conjunctiva disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-09-26T00:00:00.000Z</StatusDate><Source id="626285" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19658">Sankyo Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="79">Corneal disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-09-26T00:00:00.000Z</StatusDate><Source id="626285" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19658">Sankyo Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3016">Xerophthalmia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-09-26T00:00:00.000Z</StatusDate><Source id="626285" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="19670">Santen Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1146">Conjunctiva disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-03-31T00:00:00.000Z</StatusDate><Source id="1091916" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19670">Santen Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3016">Xerophthalmia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-03-31T00:00:00.000Z</StatusDate><Source id="1091916" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19670">Santen Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1146">Conjunctiva disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-03-31T00:00:00.000Z</StatusDate><Source id="846387" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19670">Santen Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="79">Corneal disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-03-31T00:00:00.000Z</StatusDate><Source id="846387" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19670">Santen Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="79">Corneal disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-03-31T00:00:00.000Z</StatusDate><Source id="1091916" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19670">Santen Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3016">Xerophthalmia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-03-31T00:00:00.000Z</StatusDate><Source id="846387" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19670">Santen Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3016">Xerophthalmia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-09-26T00:00:00.000Z</StatusDate><Source id="626285" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19670">Santen Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1146">Conjunctiva disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-09-26T00:00:00.000Z</StatusDate><Source id="626285" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19670">Santen Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="79">Corneal disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-09-26T00:00:00.000Z</StatusDate><Source id="626285" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19670">Santen Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3016">Xerophthalmia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-11-01T00:00:00.000Z</StatusDate><Source id="755838" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19670">Santen Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1146">Conjunctiva disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-11-01T00:00:00.000Z</StatusDate><Source id="755838" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19670">Santen Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="79">Corneal disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-11-01T00:00:00.000Z</StatusDate><Source id="755838" type="SERIAL"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01596"><Name>PPAR gamma</Name><SwissprotNumbers><Swissprot>O18924</Swissprot><Swissprot>O18971</Swissprot><Swissprot>O19052</Swissprot><Swissprot>O62807</Swissprot><Swissprot>O88275</Swissprot><Swissprot>P37231</Swissprot><Swissprot>P37234</Swissprot><Swissprot>P37238</Swissprot><Swissprot>P57797</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1017506">Daiichi Sankyo Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="19670">Santen Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>Cn1c2cc(ccc2nc1COc3ccc(cc3)CC4C(=O)NC(=O)S4)OC</Smiles></StructureSmiles><Deals><Deal id="108289" title="Santen to develop Sankyo's ophthalmic formulation of rivoglitazone"></Deal></Deals><PatentFamilies><PatentFamily id="1687194" number="WO-2006022450" title="Remedy for skin disease"></PatentFamily><PatentFamily id="209684" number="WO-2005039574" title="Therapeutic agent for keratoconjunctive disorder"></PatentFamily><PatentFamily id="344060" number="WO-2009107652" title="Agent for enhancing corneal epithelial barrier function"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Santen Pharmaceutical Co Ltd" id="19670"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>